Lunan Pharmaceutical Group is an Integrated pharmaceutical group, National innovative enterprise and National torch plan key high-tech enterprise that produces, researches and sells both traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products.

Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. It operates through the following geographical segments: India, Africa, Asia, Europe, North America, Australia and South America. The company was founded on July 23, 1984 and is headquartered in Mumbai, India.

Borui Biomedicine (Suzhou) Co., Ltd., established on 2001-10-26, Business scope includes research and development of macrolides,polypeptide,polysaccharide,Heterocycle,Azole,Azines,Phenyl ethers,Tetracyclines,Production of non-pharmaceutical macrolides,polypeptide,polysaccharide,Heterocycle,Azole,Azines,Phenyl ethers,Tetracyclines,Sell ​​the products produced by the company,And provide relevant technical consultation and technical services(Does not involve the scope of drug production license management and the restricted and prohibited products in the national foreign investment industry guidance catalog).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Drug import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

NCPC New Drug Research & Development Co. Ltd., a subsidiary of Province of Hebei, is a Chinese company located in Shijiazhuang. The firm manufactures and distributes medicines.

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company was founded by Jian Dong Yuan on October 26, 2001 and is headquartered in Suzhou, China.

Selectchemie AG distributes pharmaceutical products. The firm offers services to the complete long-term provision of raw materials for the pharmaceutical and food industries in all the countries in which they operate. The company is headquartered in Zurich, Switzerland.

Elan Pharma International Ltd., a subsidiary of Perrigo Co. Plc, is a company headquartered in South San Francisco, CA, that develops, manufactures and distributes pharmaceutical products.

Academisch Ziekenhuis Maastricht operates as medical research centre. The company is headquartered in Maastricht, the Netherlands.

Centrient Pharmaceuticals Netherlands BV produces green beta-lactams antibiotics. It offers active pharmaceutical ingredients and drug products for anti-infectives such as antibiotics, anti-fungals and other therapeutic classes like cholesterol lowering medicines. The company was founded in 1869 and is headquartered in Delft, the Netherlands.

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research & development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. Its products include active pharmaceutical ingredients and generic drugs. The company was founded in 1956 and is headquartered in Taizhou, China.

A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju. Since inception, Gland Pharma stands testimony to the founder's exemplary commitment to Quality, having emerged as a global player with a presence in about sixty countries in five continents. Our major share of business is from the regulated markets like USA, Canada, Europe and Australia. Our expertise includes in-house development and manufacturing of injectable products and we provide contract development and manufacturing services to global partners for high quality injectable products. We have a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions. We enjoy the distinction of having pioneered Heparin technology in India, and are world leaders in the Glycosaminoglycans (GAGs) range of molecules.

Suzhou Graphene Nanotechnology Co., Ltd. manufactures thin-layer grapheme products. The firm’s products include multi-layer graphene powder, slurry, coating and ink as conductive, thermal conductive, antistatic, anticorrosive materials and additives. The company was founded in August 2012 and is headquartered in Suzhou, China.

Borui Pharmaceutical (Suzhou) Co., Ltd., established on 2010-03-31, Business scope includes production:tablet,hard capsule,small volume injection(ampoule,Prefilled Syringes,non-terminal sterilized,Vials)***,Freeze-dried powder injection,API(Contains antineoplastic drugs);drug development;Sales of pharmaceutical intermediates;Sales of products produced by the company;Engaged in the import and export business of the above commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Shanghai Domirui Biotechnology Co., Ltd., established on 2015-10-14, Business scope includes biotechnology,medical technology,new material technology,Technology development in the field of detection technology,technical consulting,Technical Services,technology transfer,Biological reagents for non-clinical diagnosis,Laboratory reagents and consumables(In addition to dangerous goods),cosmetic,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),Research and development of pharmaceutical equipment,Sales,food,Research and development of health products,food sales,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Shenzhen Hybio Pharmaceutical Co., Ltd. (翰宇药业) is a high-tech enterprise which is engaged in research, development, production, and sales of polypeptide drugs. On the basis of strict production management and quality control according to the GMP strictly, it breaks through the bottle-neck of the polypeptide drugs' large-scale production technology by means of introduction digestion, independent innovation, and any other patterns. Shenzhen Hybio Pharmaceutical has successively applied for 38 patents, with 5 patents for invention, 7 national new drug certificates, 5 new drug clinical trial permissions, and 45 drug registration letters. The drugs are mainly used to treat diseases such as digestive diseases, cardiovascular and cerebrovascular diseases, diabetes, infectious diseases, tumors, senile diseases, and more.

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases. We have growing sales in more than 70 countries to over 700 customers and are continually developing and expanding our product range to meet new treatment needs and to better service our customers’ requirements. This includes developing new dosage forms using Xellia’s APIs, and if required APIs sourced from our network of suppliers. To complement our dry powder fill and freeze-dried vials for injectable delivery we are also developing innovative proprietary delivery systems and formulations for topical, inhaled or injectable administration either in house or through partnerships. We also offer contract manufacturing services and custom synthesis for clinical trial material supply. Xellia is a private company, with more than 850 employees and four state-of-the-art manufacturing facilities in Norway, Denmark, Hungary and China. We operate according to current Good Manufacturing Practice (cGMP) and our facilities have received regulatory approval from all relevant authorities, including the US Food and Drug Administration (FDA). Our operational headquarters are in Copenhagen, Denmark.